Celldex Therapeutics, Inc. (CLDX)
NASDAQ: CLDX · Real-Time Price · USD
33.33
+0.74 (2.27%)
At close: Apr 14, 2026, 4:00 PM EDT
33.87
+0.54 (1.62%)
After-hours: Apr 14, 2026, 5:52 PM EDT

Celldex Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
2,6151,8071,6772,2162,1041,806
Market Cap Growth
97.18%7.76%-24.32%5.35%16.51%160.23%
Enterprise Value
2,0991,290954.371,7941,8011,399
Last Close Price
33.3327.1625.2739.6644.5738.64
PE Ratio
--6.96-10.31-13.58-18.57-23.56
PS Ratio
1692.671169.89238.93321.95892.55388.23
PB Ratio
4.213.432.255.166.454.30
P/TBV Ratio
4.203.422.184.486.413.95
P/FCF Ratio
--8.46-10.50-20.31-19.93-29.05
P/OCF Ratio
--8.57-10.63-20.66-20.28-29.65
EV/Sales Ratio
1358.54834.75135.95260.56764.26300.73
EV/EBITDA Ratio
--4.54-4.97-11.84-16.04-20.52
EV/EBIT Ratio
--4.49-4.89-11.61-15.63-19.63
EV/FCF Ratio
--6.04-5.98-16.44-17.06-22.50
Debt / Equity Ratio
0.000.000.000.000.010.00
Debt / EBITDA Ratio
-0.01-0.01-0.02-0.04-0.04-0.07
Debt / FCF Ratio
-0.02-0.02-0.03-0.06-0.05-0.07
Net Debt / Equity Ratio
-0.98-0.98-0.96-0.97-0.92-0.96
Net Debt / EBITDA Ratio
1.811.813.762.752.675.92
Net Debt / FCF Ratio
2.412.414.513.822.846.49
Asset Turnover
0.000.000.010.020.010.01
Quick Ratio
10.2110.2118.3813.6916.4124.71
Current Ratio
10.4910.4918.9113.8717.0724.86
Return on Equity (ROE)
-40.62%-40.62%-26.84%-37.45%-30.13%-22.43%
Return on Assets (ROA)
-41.79%-41.79%-31.01%-37.77%-28.90%-20.87%
Return on Invested Capital (ROIC)
-1245.28%-1245.28%-839.80%-642.40%-420.69%-257.84%
Return on Capital Employed (ROCE)
-44.73%-44.73%-32.86%-40.21%-30.24%-21.93%
Earnings Yield
-9.89%-14.36%-9.70%-7.36%-5.38%-4.24%
FCF Yield
-8.17%-11.82%-9.52%-4.92%-5.02%-3.44%
Buyback Yield / Dilution
-3.15%-3.15%-32.91%-3.33%-9.37%-44.64%
Total Shareholder Return
-3.15%-3.15%-32.91%-3.33%-9.37%-44.64%
Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q